Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
FME Stock Overview
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally.
Fresenius Medical Care KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €47.09 |
52 Week High | €71.14 |
52 Week Low | €43.53 |
Beta | 0.94 |
1 Month Change | -16.77% |
3 Month Change | -22.47% |
1 Year Change | -32.77% |
3 Year Change | -31.79% |
5 Year Change | -44.05% |
Change since IPO | 187.43% |
Recent News & Updates
Does Fresenius Medical Care KGaA (ETR:FME) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Fresenius Medical Care KGaA (ETR:FME) Will Pay A Larger Dividend Than Last Year At €1.35
Fresenius Medical Care AG & Co. KGaA's ( ETR:FME ) dividend will be increasing to €1.35 on 17th of May. This makes the...
Shareholder Returns
FME | DE Healthcare | DE Market | |
---|---|---|---|
7D | -4.8% | -3.2% | -0.1% |
1Y | -32.8% | -29.8% | -22.0% |
Return vs Industry: FME underperformed the German Healthcare industry which returned -29.9% over the past year.
Return vs Market: FME underperformed the German Market which returned -22% over the past year.
Price Volatility
FME volatility | |
---|---|
FME Average Weekly Movement | 4.2% |
Healthcare Industry Average Movement | 3.9% |
Market Average Movement | 5.6% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.9% |
Stable Share Price: FME is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: FME's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 122,635 | Rice Powell | https://www.freseniusmedicalcare.com |
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products.
Fresenius Medical Care KGaA Fundamentals Summary
FME fundamental statistics | |
---|---|
Market Cap | €13.80b |
Earnings (TTM) | €877.72m |
Revenue (TTM) | €17.96b |
15.7x
P/E Ratio0.8x
P/S RatioIs FME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FME income statement (TTM) | |
---|---|
Revenue | €17.96b |
Cost of Revenue | €12.83b |
Gross Profit | €5.13b |
Other Expenses | €4.25b |
Earnings | €877.72m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 02, 2022
Earnings per share (EPS) | 3.00 |
Gross Margin | 28.56% |
Net Profit Margin | 4.89% |
Debt/Equity Ratio | 59.3% |
How did FME perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield45%
Payout RatioValuation
Is FME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FME?
Other financial metrics that can be useful for relative valuation.
What is FME's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | €13.80b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.5x |
Enterprise Value/EBITDA | 10.5x |
PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does FME's PE Ratio compare to its peers?
FME PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 26x |
Price-To-Earnings vs Peers: FME is good value based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (26x).
Price to Earnings Ratio vs Industry
How does FME's PE Ratio compare vs other companies in the Healthcare Industry?
Price-To-Earnings vs Industry: FME is expensive based on its Price-To-Earnings Ratio (15.7x) compared to the German Healthcare industry average (15.7x)
Price to Earnings Ratio vs Fair Ratio
What is FME's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 15.7x |
Fair PE Ratio | 29.6x |
Price-To-Earnings vs Fair Ratio: FME is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (29.6x).
Share Price vs Fair Value
What is the Fair Price of FME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FME (€47.09) is trading below our estimate of fair value (€129.65)
Significantly Below Fair Value: FME is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: FME is good value based on its PEG Ratio (0.8x)
Discover undervalued companies
Future Growth
How is Fresenius Medical Care KGaA forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
18.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FME's forecast earnings growth (18.7% per year) is above the savings rate (-0.05%).
Earnings vs Market: FME's earnings (18.7% per year) are forecast to grow faster than the German market (8.3% per year).
High Growth Earnings: FME's earnings are forecast to grow, but not significantly.
Revenue vs Market: FME's revenue (5.8% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: FME's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FME's Return on Equity is forecast to be low in 3 years time (10.8%).
Discover growth companies
Past Performance
How has Fresenius Medical Care KGaA performed over the past 5 years?
Past Performance Score
1/6Past Performance Score 1/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-8.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FME has high quality earnings.
Growing Profit Margin: FME's current net profit margins (4.9%) are lower than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: FME's earnings have declined by 8.5% per year over the past 5 years.
Accelerating Growth: FME's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: FME had negative earnings growth (-22.4%) over the past year, making it difficult to compare to the Healthcare industry average (44.5%).
Return on Equity
High ROE: FME's Return on Equity (7.7%) is considered low.
Discover strong past performing companies
Financial Health
How is Fresenius Medical Care KGaA's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: FME's short term assets (€8.0B) exceed its short term liabilities (€6.4B).
Long Term Liabilities: FME's short term assets (€8.0B) do not cover its long term liabilities (€13.8B).
Debt to Equity History and Analysis
Debt Level: FME's net debt to equity ratio (51.3%) is considered high.
Reducing Debt: FME's debt to equity ratio has reduced from 72.9% to 59.3% over the past 5 years.
Debt Coverage: FME's debt is well covered by operating cash flow (28.3%).
Interest Coverage: FME's interest payments on its debt are well covered by EBIT (6.3x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Fresenius Medical Care KGaA current dividend yield, its reliability and sustainability?
Dividend Score
5/6Dividend Score 5/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
2.87%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FME's dividend (2.87%) is higher than the bottom 25% of dividend payers in the German market (1.47%).
High Dividend: FME's dividend (2.87%) is low compared to the top 25% of dividend payers in the German market (4.53%).
Stability and Growth of Payments
Stable Dividend: FME's dividends per share have been stable in the past 10 years.
Growing Dividend: FME's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (45.1%), FME's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (25.1%), FME's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Rice Powell (66 yo)
18.42yrs
Tenure
€5,424,000
Compensation
Mr. Robert Maurice Powell, Jr., also known as Rice, has been the Chief Executive Officer and Chairman of Management at Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & C...
CEO Compensation Analysis
Compensation vs Market: Rice's total compensation ($USD5.72M) is about average for companies of similar size in the German market ($USD5.63M).
Compensation vs Earnings: Rice's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: FME's management team is considered experienced (2.6 years average tenure).
Board Members
Experienced Board: FME's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Fresenius Medical Care AG & Co. KGaA's employee growth, exchange listings and data sources
Key Information
- Name: Fresenius Medical Care AG & Co. KGaA
- Ticker: FME
- Exchange: XTRA
- Founded: 1996
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: €13.799b
- Shares outstanding: 293.03m
- Website: https://www.freseniusmedicalcare.com
Number of Employees
Location
- Fresenius Medical Care AG & Co. KGaA
- Else-KrOener Strasse 1
- Bad Homburg
- Hessen
- 61352
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.